Clinical features and risk factors for upper gastrointestinal bleeding in children: a case-crossover study.
OBJECTIVE
This population-based survey was conducted to provide a formal description of upper gastrointestinal bleeding (UGIB) in children on a nationwide basis and assess the contribution of risk factors, principally nonsteroidal anti-inflammatory drugs (NSAID).


METHODS
A case-crossover study of UGIB patients aged between 2 months and 16 years was conducted in France. Medical data were collected by physicians, and personal risk factors and exposure to drugs during the month preceding the onset of the bleeding was ascertained by a standardised telephone interview with parents. The odds ratios for UGIB and NSAID was assessed by comparing exposure during the 7 days preceding the date of hospitalisation and the 21st to the 28th days before that date.


RESULTS
A total of 177 children with UGIB were included over 2 years. Eighty-three children had taken at least one NSAID before the index date, among which 58 were ibuprofen, 26 aspirin and nine others. The adjusted odds ratio (OR) of exposure was 8.2 [95% confidence interval (CI) 2.6-26.0] for NSAIDs altogether, and this was 10.0 (95% CI 2.0-51.0) for ibuprofen and 7.3 (95% CI 0.9-59.4) for aspirin. There was no increased risk associated with NSAIDS for oesophageal lesion [OR = 1.0 [(5% CI:0.2-7.2)].


CONCLUSIONS
The study confirms that UGIB is rare but that some cases may be avoided, as one third of the cases was attributable to exposure to NSAID at doses used for analgesic or antipyretic purposes, which may be attained with alternative therapy. The findings from this study call for more caution in prescribing NSAIDS to children.
Grimaldi-Bensouda
Lamiae
L
Inserm U657 Pharmacoepidemiology Unit, Paris, France.
Abenhaim
Lucien
L
Michaud
Laurent
L
Mouterde
Olivier
O
Jonville-Béra
Annie Pierre
AP
Giraudeau
Bruno
B
David
Benoît
B
Autret-Leca
Elisabeth
E
D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D016001:Confidence Intervals; D018592:Cross-Over Studies; D004384:Duodenoscopy; D004945:Esophagoscopy; D005260:Female; D005602:France / Q000453:epidemiology; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced* / Q000453:epidemiology*; D005773:Gastroscopy; D006306:Health Surveys; D006801:Humans; D007052:Ibuprofen / Q000009:adverse effects; D007407:Interviews as Topic; D008297:Male; D016017:Odds Ratio; D012307:Risk Factors
D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin; D007052:Ibuprofen
Epidemiology. 1997 Jan;8(1):18-24
9116088
Arch Neurol. 2003 Apr;60(4):504-9
12707063
Gastroenterol Clin North Am. 2000 Mar;29(1):37-66, v
10752017
Br J Clin Pharmacol. 2005 Jun;59(6):718-23
15948937
Drug Saf. 2004;27(6):411-20
15144234
Best Pract Res Clin Gastroenterol. 2008;22(2):209-24
18346679
Epidemiology. 2001 Sep;12(5):570-6
11505178
J Clin Epidemiol. 2001 Dec;54(12):1218-27
11750190
J Clin Epidemiol. 1994 Jul;47(7):731-7
7722586
Am J Hematol. 1994 Dec;47(4):336-7
7977313
Rev Gastroenterol Disord. 2004;4 Suppl 4:S33-41
15580145
JAMA. 1995 Mar 22-29;273(12):929-33
7884951
Am J Epidemiol. 1991 Jan 15;133(2):144-53
1985444
J Rheumatol. 1995 Jun;22(6):1149-51
7674245
Arch Intern Med. 1988 Feb;148(2):281-5
3257680
Gut. 1991 Jul;32(7):730-4
1855677
Dig Dis. 2006;24(1-2):189-94
16699277
Gut. 2003 Feb;52(2):260-3
12524410